NeuBase Therapeutics (NBSE) 10-Q2014 Q1 Quarterly report

Filed: 14 Feb 14, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: ability, abnormal, agent, Allegro, Allergan, appeal, aptamer, asset, Avastin, billion, Branch, breaking, cannibalization, Central, Chasen, close, CNV, combination, commercial, compete, competing, competition, confidentiality, core, creation, DARPin, delivery, diabetic, diagnosed, displace, DME, dry, edema, embark, exudative, formation, Fovista, frequent, frequently, half, head, industry, innovative, integrin, invasive, iSonep, IST, Japan, kinase, Kobe, leaky, license, LPath, Martin, medical, minimal, monetize, monotherapy, monthly, move, National, neck, NEI, nutritional, Occlusion, older, oncology, Ophthotech, Palliative, pending, personnel, Pfizer, pipeline, podium, prevalence, Proliferative, pursuing, recruiting, Retinal, Retinopathy, selected, settle, settlement, steroid, successfully, supportive, therapeutic, transition, tyrosine, undisclosed, Vein, worldwide, Xcovery, yearly

Removed: active, allocated, analyzed, applicable, applied, assessed, assigned, atrophy, Barcelona, calculation, caption, carrying, categorization, classification, classify, committee, comparable, conducting, conform, consistent, convert, corroborated, derived, description, determining, discretion, embedded, estimate, event, expire, extend, external, fatigue, hierarchy, history, identified, incorporated, input, instrument, laboratory, Lattice, leading, liability, lowest, marked, maturity, measure, measured, measurement, measuring, method, methodology, observable, produce, qualify, quoted, readily, realizable, receivable, Reconciliation, reflective, relating, remove, reset, scheduled, sheet, Spain, strategic, subscription, unadjusted, vary, warranty, weighted

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

NBSE similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Ohr Pharmaceutical, Inc. 10-Q

Exhibit 32.2

Certification of Principal Financial Officer

Pursuant to 18 U.S.C Section 1350,

As Adopted Pursuant to Section 906 of the

Sarbanes-Oxley Act of 2002

Not Filed Pursuant to the Securities Exchange Act of 1934

In connection with the Quarterly Report of Ohr Pharmaceutical, Inc. (the “Company” ) on Form 10-Q for the period ending December 31, 2013, as filed with the Securities and Exchange Commission on the date hereof (the “Report” ), I, Sam Backenroth , Principal Financial Officer, of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:


	1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: February 14, 2014

/s/ Sam Backenroth
Name: Sam Backenroth
Title: Principal Financial Officer